Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies.

Curr Neuropharmacol · 2021 · PMC8686309 · PMID 32933463

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

extremely significantno p-value reported

Both assays are fundamental for drug development; the text that follows will focus on the cell-based assay since it has technical advantages that seem to be extremely significant for the development of drugs for genetic epilepsies.

also in 7,787 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.